Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
View Digital Edition
Drug Profiles/Updates
The Effect of Atazanavir on Doxorubicin Pharmacokinetics: A Case Report
Neha Umesh Sheth, PharmD, AAHIVP, BCPS
,
Steven Gilmore, PharmD, BCOP
,
Kenneth S. Bauer Jr, PharmD, PhD
,
Saranya Chumsri, MD
Read More
Drug Profiles/Updates
Palifermin Use for the Prevention of Chemotherapy-Induced Oral Mucositis in Anal Cancer: A Case Report
Amanda Brahim, PharmD, BCPS
,
Mohammed Ibrahim, PharmD, CRPH, BCOP, BCPS
,
Tim Nguyen, MD
,
Zahava Ohana, PharmD
Read More
From the Literature
Rituximab Maintenance Prolongs Progression-Free Survival in Patients with Relapsed Follicular Lymphoma Undergoing High-Dose Chemotherapy and Autologous Transplantation
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
Read More
From the Literature
Crizotinib Superior to Standard Chemotherapy in Patients with ALK-Positive Lung Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
Read More
From the Literature
Neoadjuvant Lapatinib and Trastuzumab with Hormonal Therapy and No Chemotherapy Beneficial in Patients with HER2 Breast Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
Read More
Results 1 - 5 of 5